인트론바이오

048530KOSDAQ

52.8 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 9.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IntronBio focuses on developing biopharmaceuticals based on bacteriophage technology and molecular diagnostic solutions. The company's drug development division targets antibiotic-resistant bacterial infections and immune therapies, while its diagnostic division produces molecular test kits, including COVID-19 diagnostic products, contributing to revenue.

Number of Employees

77people

Average Salary

64.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.27Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-11.66Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.52Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼21.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼55.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.0% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
인트론바이오, '희토류 바이오 정제' 산업부 국책과제 주관연구기관 .....
인트론바이오가 첨단바이오신소재 국책과제 주관기관으로 선정되어 기술 확장 및 산학연 협력 강화로 긍정적 전망.
Positive
인트론바이오, 분자진단 핵심 바이오소재 국산화…공정 기술 확보
인트론바이오가 돼지 유래 RNase 억제제의 정제 기술을 확보하여 분자진단 분야에서의 국산화를 성공적으로 이루어냈다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 2,870Won52-week high 6,65052-week low 2,330

1-month return5.0Point

1m +9.75% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기타경영사항(자율공시) ([국책과제선정] AI설계 기능성 단백질 기반 바이오 흡착 소재 제조 및 이를 이용한 도시광산형 주력산업용 희토류 고선택적 회수·정제 기술 개발)2026-09-02
Neutral주식등의대량보유상황보고서(일반)2026-08-27
Neutral반기보고서 (2026.06)2026-08-14